Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Roivant Sciences Ltd. (ROIV)

5.175   0.015 (0.29%) 11-28 11:07
Open: 5.12 Pre. Close: 5.16
High: 5.265 Low: 5.07
Volume: 249,221 Market Cap: 3,754(M)

Technical analysis

as of: 2022-11-28 10:51:55 AM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 6.68     One year: 7.8
Support: Support1: 4.71    Support2: 4.09
Resistance: Resistance1: 5.71    Resistance2: 6.68
Pivot: 5.17
Moving Average: MA(5): 5.04     MA(20): 5.2
MA(100): 4.22     MA(250): 5.22
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 42.9     %D(3): 33.3
RSI: RSI(14): 54.8
52-week: High: 16.76  Low: 2.51
Average Vol(K): 3-Month: 1,208 (K)  10-Days: 1,162 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ROIV ] has closed above bottom band by 49.1%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.24 - 5.26 5.26 - 5.28
Low: 5.05 - 5.07 5.07 - 5.09
Close: 5.12 - 5.16 5.16 - 5.2

Company Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Headline News

Tue, 22 Nov 2022
Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher - Simply Wall St

Mon, 14 Nov 2022
Roivant Sciences Ltd. Misses Q2 EPS by 4c By Investing.com - Investing.com

Mon, 14 Nov 2022
Health Care Sector Update for 11/14/2022: DCGO,ROIV,STSA - Nasdaq

Mon, 14 Nov 2022
Roivant Sciences (NASDAQ:ROIV) Shares Gap Up on Insider Buying Activity - MarketBeat

Mon, 14 Nov 2022
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates - Nasdaq

Fri, 11 Nov 2022
Pre-Market Earnings Report for November 14, 2022 : TSN, ACM, XRAY, TSEM, MNDY, ROIV, TWKS, YOU, QFIN, FREY, OTLY, VRDN - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 725 (M)
% Held by Insiders 1.371e+008 (%)
% Held by Institutions 39.2 (%)
Shares Short 11,270 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 0
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 99
Return on Equity (ttm) -24.9
Qtrly Rev. Growth 5.042e+007
Gross Profit (p.s.) 0.03
Sales Per Share 0.06
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -858 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 83.86
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 1.231e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.